Wildcard: BICO, Bioprinting, and Bioconvergence

Industry Focus

The Motley Fool

Interview, Money, Consumergoods, Business, Businessnews, Ceo, Technology, Investing, Stocks, Energy, Fool, Financial, Economy, Healthcare, News, Banking, Motley, Tech, Business News, Investments

4.6 • 854 Ratings

🗓️ 15 December 2021

⏱️ 26 minutes

🔗️ Recording | iTunes | RSS

🧾️ Download transcript

Summary

We get back to Wednesday's healthcare roots with a rundown on BICO Group, a Sweden-based business that enables researchers and scientists to model, build, test, analyze and observe 3-D printed cells, tissues and organs.

This company helps researchers reduce the time and cost of identifying potentially efficacious drugs and can help provide initial results on whether drug compounds are safe and effective before having to test them on animals or humans.

We talk through the huge implications it could have for research in life sciences and personalized medicine and try to clear up some of the jargon around the company.

Stocks: (OM:BICO)

Check out more of our content here:

Podcasts

Youtube

Twitter

Reach us by Email @ [email protected]

Transcript

Click on a timestamp to play from that location

0:00.0	Welcome to Industry Focus. The Podcast that dives into a different sector of the stock market each day.
0:11.0	I'm your host Emily Flippin. I'm Jason Moser. I'm Nick Seyple. I'm Dylan Lewis. And today
0:16.0	we're talking financials. Today we're talking consumer goods. Wild Card Wednesday.
0:20.4	And we're talking energy. And today we're talking tech.
0:23.7	Let's dive in.
0:26.3	It's Wednesday, December 15th, and we're talking about a picks and shovels,
0:29.6	life science company, psycho group.
0:31.7	I'm your host, Dylan Lewis Lewis and I'm joined by Fool
0:33.2	dot com analyst Yasser El Shimi. Yasser how's it going? I'm doing well how about you
0:38.8	Dylan? Doing all right I think this this is going to be a fun show for folks that have been longtime
0:44.7	listeners and desperately miss the Wednesday health care episodes. We are going
0:49.7	to be going deep into a business that I had to learn a lot about for the show, had to learn a lot of words.
0:55.0	And I think, yeah, so we're probably going to have to do a lot of defining and get ahead of some of the jargon we're going to be dropping on this episode.
1:00.0	Don't worry. We're doing the learning together. I think I have to start with a disclaimer that I'm not a medical doctor, I'm not a scientific researcher.
1:07.0	So a lot of this stuff, you know, it's okay that it's hard, it's complicated complicated a lot of it is full jargon so we'll
1:16.2	we'll do our best to try and you know make it as straightforward as possible.
1:20.3	Yeah and I'll say like I love getting new and different ideas in front of me. I'm sure our
1:25.8	listeners do too. I mean I tend to be more of a tech investor, but I learn everything.
1:30.8	I learn from everything no matter what gets thrown on my radar, you know, and it kind of
1:34.6	broadens your horizons, even if it's not an investable idea for you.
1:37.2	It's probably going to teach you a little bit of something about where the world is going.
1:40.3	And that is certainly the case with this company.
	...

Please login to see the full transcript.

Previous episode | Next episode

Disclaimer: The podcast and artwork embedded on this page are from The Motley Fool, and are the property of its owner and not affiliated with or endorsed by Tapesearch.

Generated transcripts are the property of The Motley Fool and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.